Vancomycin
Dr. Burrascano's Protocol (2005)
Confirmed By
Linden Hu's New Study(s)
Vancomycin Studies
Dr. Joseph Burrascano &
Lyme Monster- Linden T. Hu
August 2018- Over a decade ago (2005), Dr. Joseph Burrascano, Jr. wrote about successfully treating patients with difficult cases of Lyme disease with vancomycin. See his pdf at the bottom of this page.
Effectiveness of Vancomycin in Treatment-Resistant Lyme
J. J. Burrascano., Jr., M.D. East End Medical Associates, P.C. East Hampton, NY
Eighteen years later, in August 2018, a group of authors published on the ability of vancomycin to clear out Lyme organisms in lab experiments, as if it were a new concept. It wasn't.
~ ~ ~
Antimicrob Agents Chemother. 2018 Aug 20. pii: AAC.01201-18. doi: 10.1128/AAC.01201-18. [Epub ahead of print]
Identifying vancomycin as an effective antibiotic for killing Borrelia burgdorferi.
Wu X1, Sharma B2, Niles S1, O'Connor K1, Schilling R1, Matluck N1, D'Onofrio A1, Hu LT2, Lewis K3.
1 Antimicrobial Discovery Center, Northeastern University, Boston, MA.
2 Tufts Medical Center, Boston, MA.
3 Antimicrobial Discovery Center, Northeastern University, Boston, MA. k.lewis@neu.edu.
Link to Study
https://sites.google.com/site/marylandlyme/treatment/antibiotic-resistance-with-lyme-treatment
Three years earlier (2015), vancomycin had already been determined to be more affective than Doxycycline and other drugs typically used, and that information was published in a study by Sharma, et. al. See information & comments about that study here.
Example... Quote- "Vancomycin effectively killed growing cells of B. burgdorferi, but not persisters, and was comparable to ceftriaxone (not shown)."
In both the 2015 and 2018 vancomycin studies, one author stands out- Dr. Linden T. Hu.
This is note-worthy due to the fact Dr. Hu not only worked hand in hand with the IDSA Lyme guideline authors and was funded in the early years by NIH's Edward McSweegan, he participated with them in their continuing attacks against Lyme patients, advocates and our doctors.
This was occurring while Linden T. Hu was also applying for and had received at least 99 federal grants (totalling over 17.3 MILLION DOLLARS) to perform supposedly UNBIASED Lyme related studies.
The tax-payer's money helped fund Hu's so-called "supporting study" that he and his IDSA guideline buddies continue to use today to deny the existence of chronic Lyme, and in turn our abilty to get treatment for it.
Hu, having already determined Doxycycline was not affective and vancomycin was, in 2016 both he & Wormser ignored their own evidence and stated-
"Recent evidence supports treating patients with erythema migrans for no longer than 10 days when doxycycline is used and prescription of a 14-day course of oral doxycycline for early neurologic Lyme disease in ambulatory patients." Source
Knowing for over a decade that Doxycycline was not able to kill all of the Borrelia organisms, and vancomycin (a more expensive drug) showed promise, Hu continued to accept federal funding, yet continued to publish against patients being treated with anything other than an initial short course of antibiotics (Doxycycline) for chronic Lyme, and continued to participate in the attacks against Lyme patients, advocates and doctors.
This is one of the reasons he has been referred to as a Lyme Monster.
joeVanco.pdfBUT WAIT...
WORMSER DOESN'T LIKE THIS!!!
DOESN'T EVEN WANT ANYONE TO TRY IT!
Wien Klin Wochenschr. 2019 May 10. doi: 10.1007/s00508-019-1505-6. [Epub ahead of print]
Evaluation of the clinical relevance of vancomycin for the treatment of Lyme disease.
Wormser GP1, Barbour AG2.
1 Division of Infectious Diseases, New York Medical College, 40 Sunshine Cottage Road, Skyline Office #2N-F05, 10595, Valhalla, NY, USA. gwormser@nymc.edu.
2 Departments of Medicine and Microbiology & Molecular Genetics, University of California Irvine, 92697, Irvine, CA, USA.
Abstract
Vancomycin is active in vitro and in vivo in mouse systems against Lyme disease borrelia; however, there are no published data on the efficacy of vancomycin in patients with Lyme disease and no convincing theoretical advantages of vancomycin over the currently used and highly effective orally administered antimicrobial agents, including doxycycline, amoxicillin and cefuroxime axetil.
In addition, vancomycin may cause a wide variety of potentially serious adverse effects and requires the placement of an intravenous catheter.
It is concluded that vancomycin is a much less attractive option for the treatment of patients with early Lyme disease (or any other manifestation of Lyme disease), compared with the antimicrobials currently being used.
Based on available evidence, clinical studies to evaluate the safety and efficacy of vancomycin for Lyme disease cannot be recommended.
KEYWORDS: Animal models; Antibiotics; Borrelia burgdorferi; Borreliella burgdorferi; Lyme borreliosis
PMID: 31076888
DOI: 10.1007/s00508-019-1505-6
Link Here
https://www.ncbi.nlm.nih.gov/pubmed/31076888
Last Updated- May 2019
Lucy Barnes